Summary:
- The article discusses the presentation of long-term transplant-free survival data for Lomecel-B, a cellular therapy developed by Longeveron, in patients with Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons Society (CHSS) 51st Annual Meeting.
- Lomecel-B is a cell-based therapy derived from the medicinal signaling cells (MSCs) found in the bone marrow of young, healthy adult donors, and it has shown promise in improving outcomes for HLHS patients.
- The data presented demonstrates that Lomecel-B treatment has resulted in improved transplant-free survival rates for HLHS patients, highlighting the potential of this therapy to address a significant unmet medical need in this patient population.